

## Figure S6. Structural features in S1PR1 upon activation

(a) Structural superposition of S1P-bound activated S1PR3 and ML056-bound inactivated S1PR1. The side-chain of residue  $F^{5.47}$  in SPR3 is observed to exhibit notable displacement whereas the  $F^{6.52}$  in both structures adopt the same conformation. Medium spring greer, S1PR3; S1P, maroon; gray, S1PR1; dodger blue, ML056.

(b) Effects of the mutants of S1PR1 on siponimod-induced cAMP inhibition. Bars represents difference in calculated potency (pEC<sub>50</sub>) of agonist for mutations relative to WT of S1PR1. Data are colored according to extent of effect. ND, not detected, \*p < 0.1, \*\*\*p < 0.001 (one-way analysis of variance [ANOVA] followed by the Dunnett's test, compared with the response of WT). Data represent mean  $\pm$  SEM from three independent experiments performed in triplicate.

(c) Structural comparison MDMB-Fubinaca (FUB) bound CB1 (agonist, light salmon, PDB: 6N4B) with Taranabant bound CB1 (antagonist, sea green, PDB: 5U09) reveals the toggle switches  $F^{3.36}$ -W<sup>6.48</sup> activation mechanism in receptor.

(d) Structural rearrangement of  $P^{5.50}$ - $I^{3.40}$ - $F^{6.44}$  motif in S1PR1(inactive PDB: 3V2Y, gray; active, teal),  $\beta_2AR$  (inactive PDB: 2RH1, yellow; active PDB: 3SN6, plum) and  $\mu OR$  (inactive PDB: 4DKL, dark olive green; active PDB: 6DDE, light green) upon activation. S1PR1 is absent of proline at the position 5.50, which is substituted by leucine.

(e-g) Superposition of microswitches between S1PR1 and S1PR5.  $P^{5.50}$ -I<sup>3.40</sup>-F<sup>6.44</sup> motif (e);  $E^{3.49}$ -R<sup>3.50</sup>-Y motif (f); N-P<sup>7.50</sup>xxY<sup>7.53</sup> motif (g).